Isis Receives Macugen-Related Milestone Payment from Eyetech
Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Eyetech Pharmaceuticals in connection with Eyetech’s filing of a new drug application with US regulators for the age-related macular degeneration treatment Macugen.
Although Macugen is not an antisense agent, Eyetech licensed certain patents from Isis needed to develop, manufacture, and commercialize the drug, according to Isis.